[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paroxysmal-hemicrania\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paroxysmal-hemicrania":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100433958","phase-2-clinical-trial-of-endoscopically-guided-injection-of-exparel-bupivacaine-for-the-treatment-of-craniofacial-pain-100433958",false,"NCT04930887","Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain","Prospective, Randomized, Double-blinded, Placebo-controlled, Cross-over Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) Towards the Ipsilateral Pterygopalatine Fossa for the Treatment of Craniofacial Pain","Inclusion Criteria:\n\n* Patients with a chief complaint of craniofacial pain (migraine, cluster headache, trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, paroxysmal hemicrania) who has Stanford Pain \\& ENT clinic visit\n\nExclusion Criteria:\n\n* age \\\u003C18 or \\>80\n* pregnant women\n* economically disadvantaged (not able to afford clinic visits\u002Ftreatments)\n* decisionally impaired (unable to obtain informed consent)\n* has allergy to bupivacaine\n* unable or unwilling to participate plans to participate in another clinical study at any time during this study","ALL","18 Years","80 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may positively impact craniofacial pain and functional outcomes, in patients who experience relief with the topical application of Lidocaine (routinely given prior to almost all ENT endoscopy).",[27,28,29,30,31,32],"Craniofacial Pain","Migraine","Cluster Headache","Trigeminal Autonomic Cephalgia","Sphenopalatine Ganglion Neuralgia","Paroxysmal Hemicrania","RECRUITING","2026-04-23",{"date":36,"type":37},"2026-04-27","ACTUAL",{"date":39,"type":37},"2023-02-01",{"date":41,"type":21},"2030-06",{"name":43,"class":44},"Stanford University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100278898","the-will-erwin-headache-research-center---cluster-headache-study-100278898","NCT02910323","The Will Erwin Headache Research Center - Cluster Headache Study","The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia","WEC1","Inclusion Criteria:\n\n* Diagnosis of a trigeminal autonomic cephalalgia according to the International Headache Classification including episodic cluster headache, chronic cluster headache, episodic paroxysmal hemicrania, chronic paroxysmal hemicrania, episodic short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), chronic SUNCT, episodic short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA), chronic SUNA, and hemicrania continua. OR Diagnosis of a trigeminal neuralgia according to the International Headache Classification, including classical trigeminal neuralgia and symptomatic trigeminal neuralgia.\n* Able to provide HIPAA authorization to share prior medical records\u002Fimaging.\n\nExclusion Criteria:\n\n* Life expectancy less than 1 year, co-existing disease or other characteristic that precludes appropriate diagnosis of a trigeminal autonomic cephalalgia or trigeminal neuralgia.\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give informed consent.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Inclusion criteria is willingness to consent and be of age 18 and older",true,{"count":56,"type":21},1500,"OBSERVATIONAL","The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia is a prospective, multicenter, observational research network for subjects with Cluster Headache and\u002For Trigeminal Neuralgia.",[29,60,32,61,62,63],"Cluster Headaches and Other Trigeminal Autonomic Cephalgias","SUNCT","Hemicrania Continua","Trigeminal Neuralgia","2026-02-13",{"date":66,"type":37},"2026-02-18",{"date":68,"type":4},"2016-07-12",{"date":70,"type":21},"2035-12",{"name":72,"class":44},"The University of Texas Health Science Center, Houston"]